Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Walgreens Participation In 340B Program Probed By Sen. Grassley

This article was originally published in The Pink Sheet Daily

Executive Summary

Grassley suggests concern that the big pharmacy chain’s participation in the program may lead to diversion, in which drugs purchased at discounted 340B pricing are dispensed to insured individuals, allowing the pharmacy to profit from the difference in payments.

You may also be interested in...



340B Contract Pharmacies: Antivirals Are Top Drugs Dispensed

In the first study to analyze data for 340B-discounted drugs dispensed at contract retail pharmacies, researchers found antivirals were dispensed at more than 10 times the rate seen for all scripts at Walgreens, the largest 340B contract pharmacy. The largest source of 340B contract pharmacy prescriptions was tuberculosis clinics.

340B Lobby Group Seeks Bill Changing Hospital Eligibility For Discount Drugs

A group supported by drug manufacturers and pharmacy benefit managers – the Alliance for Integrity and Reform of 340B – is pushing Congress to alter how hospitals qualify for discounted drugs under the 340B program.

Senior Senators Seek Details On Government Audits Of 340B Entities

Top Republicans on two Senate health committees are joined by House members in seeking answers on an HHS review of entities receiving 340B drug discounts, including the process and consequences of audits and decertification.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS076086

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel